Pharmacyclics Reaches New 52-Week High (PCYC)

Pharmacyclics Incorporated (Nasdaq:PCYC) hit a new 52-week high Wednesday as it is currently trading at $96.44, above its previous 52-week high of $95.85 with 431,164 shares traded as of 9:46 a.m. ET. Average volume has been 814,400 shares over the past 30 days.
By TheStreet Wire ,

NEW YORK (

TheStreet

) --

Pharmacyclics Incorporated

(Nasdaq:

PCYC

) hit a new 52-week high Wednesday as it is currently trading at $96.44, above its previous 52-week high of $95.85 with 431,164 shares traded as of 9:46 a.m. ET. Average volume has been 814,400 shares over the past 30 days.

Pharmacyclics has a market cap of $6.32 billion and is part of the health care sector and drugs industry. Shares are up 50.2% year to date as of the close of trading on Tuesday.

Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates

Pharmacyclics

as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share. You can view the full

Pharmacyclics Ratings Report

.

See all

52-week high stocks

or get investment ideas from our

investment research center

.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

.

null

Loading ...